Drugs / BLXA4
BLXA4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02342691 | Apr 2015 → Sep 2017 | gingivitis | The Forsyth Institute | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLXA4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02342691 ↗ |
| Known as | Benzo-lipoxin a4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297266 ↗ |
| Known as | Benzo-lxa-4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297266 ↗ |
| Known as | ClinRinse-1 | “The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution” NCT02342691 ↗ |
| Known as | methyl ester-benzo-lipoxin A4 | “One hundred twenty-seven (127) individuals were randomized to daily use of an oral rinse containing a LXA4 mimetic, methyl ester-benzo-lipoxin A4 (BLXA4), placebo rinse or a...” PMID 34589083 ↗ Sep 2021 |
| Modality | Small molecule | — CHEMBL4297266 ↗ |
| Route | Topical | “topically applied as a daily oral rinse” NCT02342691 ↗ |